Advanced Solid Tumors
Conditions
Keywords
VEGF, DLL4, Solid Tumors, bispecific antibody, anti-angiogenic
Brief summary
The purpose of this open-label, dose escalation-dose expansion, Phase 1 clinical trial is to evaluate the safety, pharmacokinetics and anti-tumor activity and determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of NOV1501 (ABL001).
Detailed description
This is an open-label, Phase 1 dose escalation and expansion study of NOV1501 (ABL001) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and the anti-tumor efficacy of ABL001 in patients with advanced solid tumors after failure of standard of care. Patients will be enrolled in two stages: a dose-escalation stage and an expansion phase. DLTs will be assessed as the primary endpoint in this trial.
Interventions
DRUGNOV1501 (ABL001)
VEGF/DLL4 targeting bispecific antibody
Sponsors
National OncoVenture
ABL Bio, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥19 year old patients with histologically or cytologically confirmed metastatic or unresectable advanced solid tumors * Lesions measured by tumor markers or by CT/MRI must be evaluable based on response evaluation criteria in solid tumors (RECIST) version 1.1. * Life expectancy ≥12 weeks * ECOG performance status ≤2 * Women of childbearing potential must have a negative pregnancy test outcome * Patients must provide written informed consent to voluntary participation in this study.
Exclusion criteria
* History of hypersensitivity reactions to any of the components of the investigational product or other drugs of the same class * Less than 4 weeks have elapsed since a major surgery and 2 weeks have elapsed since a minor surgery * New York Heart Association (NYHA) class ≥II congestive heart failure (CHF) * Persistent, clinically significant NCI-CTCAE v4.03 Grade ≥2 toxicities from the previous anticancer therapy * Severe infections or severe traumatic systemic disorders * Symptomatic or uncontrolled central nervous system (CNS) metastasis * Pregnant or lactating women or patients planning to become pregnant during the study * Participation in another clinical trial within 30 days prior to screening * Administration of antiplatelets or anticoagulants within 2 weeks prior to screening * Requiring continuous treatment with systemic NSAIDs or systemic corticosteroids * HIV or other severe diseases that warrant the exclusion from this study * Peritoneal and/or pleural fluid drainage within 28 days prior to screening * History of hemoptysis within 28 days prior to screening * Serious, untreated scar, active ulcer, or untreated fracture
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) | From time of 1st administration of ABL001 until day 21. | The maximum tolerated dose/maximum administered dose will be determined by the number of participant experiencing DLTs. The safety profile will be assessed through number of participants experiencing AEs, SAEs, abnormal laboratory parameters, vital signs and electrocardiogram (ECG) results. |
Countries
South Korea
Outcome results
None listed